Mohammad Movahedi

Assistant Professor (Status)

University of Toronto Dalla Lana School of Public Health

Canada

Research Interests

Explore related searches

Professors in Canada

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Dr. Mohammad Movahedi is an Assistant Professor at the University of Toronto Dalla Lana School of Public Health, Canada. His research primarily focuses on rheumatoid arthritis, including healthcare utilization, treatment outcomes, and the impact of social determinants of health. Dr. Movahedi has published extensively on topics such as the cost of herpes zoster infections in rheumatoid arthritis patients and vaccine uptake during the COVID-19 pandemic.

Articles (11)

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2020

Collaborators (2)

Claire Bombardier

University Health Network

CANADA

View details

Janet Pope

Professor of Medicine, Division Head Rheumatology

University of Western Ontario

CANADA

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Mohammad Movahedi

Research Interests

Explore related searches

Contact this professor

About

Articles (11)

Healthcare Utilization and Cost of Herpes Zoster Infection in Patients With Rheumatoid Arthritis: A Retrospective Cohort Study

Healthcare utilization among patients with rheumatoid arthritis, with and without herpes zoster, a retrospective administrative data linked cohort study

Which advanced treatment should be used following the failure of a first-line anti-TNF in patients with rheumatoid arthritis? 15 years of evidence from the Quebec registry RHUMADATA

Functional disability and disease activity are affected by social determinants of health in patients with rheumatoid arthritis

Retention of triple therapy with methotrexate, sulfasalazine, and hydroxychloroquine compared to combination methotrexate and leflunomide in rheumatoid arthritis

Discontinuation of tofacitinib and TNF inhibitors in patients with rheumatoid arthritis: analysis of pooled data from two registries in Canada

Investigating the tendency to use COVID-19 vaccine booster dose in Iran

Disease activity trajectories for early and established rheumatoid arthritis: Real-world data from a rheumatoid arthritis cohort

Physician- and Patient-reported Effectiveness Are Similar for Tofacitinib and TNFi in Rheumatoid Arthritis: Data From a Rheumatoid Arthritis Registry

Heterogeneity in Patient Characteristics and Differences in Treatment Across 4 Canadian Rheumatoid Arthritis Cohorts

Modified Disease Activity Score at 3 Months Is a Significant Predictor for Rapid Radiographic Progression at 12 Months Compared With Other Measures in Patients With Rheumatoid Arthritis

Collaborators (2)

Claire Bombardier

Janet Pope

Make your next move.